← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vyriad, Inc.
Rochester, MN
$4,051,899
Total funding
2
Grants
Funding over time
peak $2M · FY2017–20$2M$1.5M$1M$500K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$4,051,899 · 2
By mechanism
R44$4,051,899 · 2
Investigators at Vyriad, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$950,045
R44 · FY2019 · CA
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER$924,838
R44 · FY2018 · CA
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER$909,357
R44 · FY2019 · CA
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$823,919
R44 · FY2020 · CA
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$178,985
R44 · FY2018 · CA
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER$156,755
R44 · FY2017 · CA
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$108,000
R44 · FY2019 · CA